Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | The latest on teclistamab

Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the latest research on teclistamab, a bispecific antibody that binds to CD3 and B-cell maturation antigen (BCMA) to redirect T-cells to multiple myeloma cells. Dr Mateos talks on the likely movement of teclistamab into earlier lines of treatment in combinations and as monotherapy. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Transcript (edited for clarity)

So teclistamab is a bispecific monoclonal antibody targeting BCMA that has been evaluated and recently published. In a cohort of relapsing on refractory myeloma patients after a median of six prior lines of therapy and 80% of the patients were refractory to the conventional three drug classes: proteasome inhibitors, immunomodulatory drugs, as well as anti-CD38 monoclonal antibody. Teclistamab is an off the shelf drug that covers the medical need that we have in this triple class refractory myeloma patient because the overall response rate is over 60%, with some patients achieving VGPR and even a complete response...

So teclistamab is a bispecific monoclonal antibody targeting BCMA that has been evaluated and recently published. In a cohort of relapsing on refractory myeloma patients after a median of six prior lines of therapy and 80% of the patients were refractory to the conventional three drug classes: proteasome inhibitors, immunomodulatory drugs, as well as anti-CD38 monoclonal antibody. Teclistamab is an off the shelf drug that covers the medical need that we have in this triple class refractory myeloma patient because the overall response rate is over 60%, with some patients achieving VGPR and even a complete response. In addition, in terms of safety profile, cytokine release syndrome is present in over 70% of the patients, but mainly grade one and two in most of the patients. Some patients developed a neurotoxicity, but definitely in a very low frequency and are very well manageable. Cytopenia are also observed after the teclistamab therapy, but basically restricted to the step up dosing and cycle one and cycle two.

We don’t have any information yet about the durability of the response, although we have the opportunity to see how response deepens over time and from the pharmacokinetic and pharmacodynamics point of view, we know that there is an activation of the lymphocytes indicating that these lymphocytes are going to be redirected into the tumor needs, resulting into the killing of the plasma cells. If we consider all this efficacy and safety data, the teclistamab targeting BCMA is relevant by specific monoclonal antibody we can utilize for the triple class refractory myeloma patients. Today or in the near future when the approval of course, but in the future, the teclistamab will move to every line of therapy, a single agent, but maybe also in combination with other bispecific monoclonal antibodies or anti-CD38 monoclonal antibodies, or maybe in combination with immunomodulatory drugs.

Read more...

Disclosures

Maria-Victoria Mateos, MD, PhD, has received honoraria from lectures and participated in boards with Janssen, BMS-Celgene, AbbVie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio and Sea-Gen.